Recent Finacing
Recent Raise
RhyGaze develops gene therapies for retinal blindness, advancing an optogenetic vision‑restoration clinical candidate from IOB‑licensed IP through preclinical pharmacology/toxicology, observational endpoint studies, and first‑in‑human trials.
Focus Areas
Recent Investors
Total Raised
Funding round
Investors
